Antibody production: polyclonal-derived biotherapeutics.
Antibody based therapies using monoclonal or polyclonal antibodies are emerging as an important therapeutic approach for the treatment of a number of diseases. With increasing emphasis on new technologies associated with monoclonal antibody expression and purification, the clinical need of polyclonal therapeutics for treatment of a variety of specific illnesses and infections is often overlooked. Despite being largely abandoned in the early twentieth century due to the development of antibiotics, polyclonal antibody therapeutics are today widely used in medicine for viral and toxin neutralization and for replacement therapy in patients with immunoglobulin deficiencies. Over the past 20 years, intravenous immunoglobulins have shown beneficial immunomodulatory and anti-inflammatory effects in many illnesses. Hyperimmune antibody preparations have been used over the past century for the treatment of a variety of infectious agents and medical emergencies, including digoxin toxicity, snake envenomation and spider bites. Here, we examine the contemporary techniques and applications, and assess the future therapeutic potential, for polyclonal-derived antibody therapeutics.
Newcombe
Claire
C
Process Development Group, Protherics UK Ltd, Blaenwaun, Ffostrasol, Llandysul, Wales SA44 5JT, UK.
Newcombe
Anthony R
AR
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000917:Antibody Formation / Q000276:immunology*; D006801:Humans; D007106:Immune Sera / Q000276:immunology; D007167:Immunotherapy / Q000295:instrumentation / Q000379:methods*; D008962:Models, Theoretical
D000911:Antibodies, Monoclonal; D007106:Immune Sera